Table 1 Translational studies that employed MSC-derived exosomes to treat liver injury
From: Role of mesenchymal stem cells, their derived factors, and extracellular vesicles in liver failure
Disease/model | Origin of exosomes | Method/dose | Therapeutic capacity | References |
|---|---|---|---|---|
Carbon tetrachloride (CCl4)-induced liver injury mouse model | Human ESC-derived HuES9.E1 MSCs | Intrasplenic injection of 0.4 μg exosomes (in 100 μl PBS) | Elicited hepatoprotective effects against injury primarily by activating of proliferative and regenerative responses | Cheau Yih Tan [26] |
CCl4-induced fibrotic liver mouse model | Human umbilical cord-MSCs | Liver injection of 250 μg hucMSC-Ex of 330 μL PBS | Ameliorate liver fibrosis by inhibiting the epithelial-to-mesenchymal transition and protecting hepatocytes | Tingfen Li [27] |
CCl4-induced liver failure mouse model | Human umbilical cord MSCs | Tail vein or intragastric administration of 16Â mg/kg exosomes | Promoted the recovery of hepatic oxidant injury via the delivery of GPX1 | Yongmin Yan [28] |
D-GalN/LPS-induced liver failure mouse model | Human menstrual blood-derived stem cells | Tail vein injection of 1 μg/μl MenSC-Ex in PBS (The volume was not mentioned.) | Markedly improved liver function, enhanced survival rates, and inhibited liver cell apoptosis | Lu Chen [29] |